Table 4.
Antibiotic class | Antibiotics | Inhibition zone (mm) | MIC (μg/ml) | ||||
---|---|---|---|---|---|---|---|
DH5α | DH5α-pHI1 | DH5α-pAC2 | DH5α | DH5α-pHI1 | DH5α-pAC2 | ||
β-lactam | Ampicillin | S(27) | R(0) | S(25) | S(1) | R(256) | S(1) |
Amoxicillin-Clavulanate | S(29) | R(7) | S(20) | S(8/4) | R(64/32) | S(4/2) | |
Ceftazidime-Avibactam | S(34) | S(36) | S(35) | S(0) | S(0) | S(0) | |
Piperacillin-Tazobactam | S(26) | S(24) | I(19) | S(8/4) | S(8/4) | S(4/4) | |
Cefepime | S(36) | S(32) | S(32) | S(0) | S(0) | S(0) | |
Ceftazidime | S(34) | S(26) | S(23) | S(0) | S(0.25) | S(0) | |
Cefotaxime | S(37) | S(29) | S(29) | S(0) | S(0.125) | S(0) | |
Cefoxitin | S(22) | R(7) | S(20) | I(16) | R(64) | I(16) | |
Cefoperazone | S(35) | S(30) | S(28) | S(0) | S(0.5) | S(0) | |
Carbapenem | Imipenem | S(25) | S(26) | S(35) | S(0) | S(0.25) | S(0.25) |
Aminoglycoside | Spectinomycin | S(29) | S(22) | S(30) | – | – | – |
Kanamycin | S(30) | R(0) | S(26) | S(0.25) | R(128) | S(32) | |
Streptomycin | S(26) | S(26) | R(10) | – | – | – | |
Quinolone | Gatifloxacin | S(30) | S(29) | S(35) | S(0) | S(0.125) | S(0.125) |
Ciprofloxacin | S(31) | S(30) | S(25) | S(0) | S(0.125) | S(0.125) | |
Nalidixic acid | I(14) | R(0) | R(13) | R(128) | R(256) | R(256) | |
Diaminopyrimidine | Trimethoprim | S(35) | R(0) | S(35) | S(4) | R(256) | R(128) |
Sulfonamide | Sulfisoxazole | S(23) | S(40) | R(0) | R(512) | R(512) | R(512) |
Rifampicin | Rifampicin | S(23) | R(12) | I(18) | – | – | – |
Macrolide | Erythromycin | S(18) | R(9) | R(0) | – | – | – |
Phenicol | Chloramphenicol | S(32) | S(28) | R(11) | S(2) | S(2) | S(8) |
Tetracycline | Tetracycline | S(27) | S(26) | I(12) | S(2) | S(2) | R(64) |
Glycylcycline | Tigecycline | S(20) | S(30) | S(24) | S(0) | S(0.25) | S(0.25) |
Polymyxin | Polymyxin E | N | N | N | S(1) | S(1) | S(1) |
–, MIC breakpoint unavailable in CLSI standard.
N, Disk diffusion test not recommended in CLSI standard.